Abstract
Coordination between the amplification of the fibroblast growth factor FGF19, overexpression of its corresponding receptor FGFR4, and hyperactivation of the downstream transmembrane enzyme β-klotho has been found to play pivotal roles in mediating tumor development and progression. Aberrant FGF19-FGFR4 signaling has been implicated in driving specific tumorigenic events including cancer cell proliferation, apoptosis resistance, and metastasis by activating a myriad of downstream signaling cascades. As an attractive target, several strategies implemented to disrupt the FGF19-FGFR4 axis have been developed in recent years, and FGF19-FGFR4 binding inhibitors are being intensely evaluated for their clinical use in treating FGF19-FGFR4 implicated cancers. Based on the established work, this review aims to detail how the FGF19-FGFR4 signaling pathway plays a vital role in cancer progression and why disrupting communication between FGF19 and FGFR4 serves as a promising therapeutic strategy for disrupting cancer progression.
Original language | English (US) |
---|---|
Pages (from-to) | 17-25 |
Number of pages | 9 |
Journal | Current cancer drug targets |
Volume | 19 |
Issue number | 1 |
DOIs | |
State | Published - 2019 |
Keywords
- FGF19
- FGFR4
- cancer
- drug development
- target
- β-klotho.
ASJC Scopus subject areas
- Oncology
- Pharmacology
- Drug Discovery
- Cancer Research